Taysha Gene Therapies Quick Ratio 2020-2024 | TSHA
Historical quick ratio values for Taysha Gene Therapies (TSHA) over the last 10 years.
| Taysha Gene Therapies Quick Ratio Historical Data |
| Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
| 2024-09-30 |
$0.00B |
$0.03B |
0.00 |
| 2024-06-30 |
$0.00B |
$0.03B |
0.00 |
| 2024-03-31 |
$0.00B |
$0.04B |
0.00 |
| 2023-12-31 |
$0.00B |
$0.04B |
0.00 |
| 2023-09-30 |
$0.00B |
$0.18B |
0.00 |
| 2023-06-30 |
$0.00B |
$0.05B |
0.00 |
| 2023-03-31 |
$0.00B |
$0.05B |
0.00 |
| 2022-12-31 |
$0.00B |
$0.06B |
0.00 |
| 2022-09-30 |
$0.00B |
$0.03B |
0.00 |
| 2022-06-30 |
$0.00B |
$0.04B |
0.00 |
| 2022-03-31 |
$0.00B |
$0.05B |
0.00 |
| 2021-12-31 |
$0.00B |
$0.05B |
0.00 |
| 2021-09-30 |
$0.00B |
$0.04B |
0.00 |
| 2021-06-30 |
$0.00B |
$0.03B |
0.00 |
| 2021-03-31 |
$0.00B |
$0.02B |
0.00 |
| 2020-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2020-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2020-06-30 |
$0.00B |
|
0.00 |
| 2020-03-31 |
$0.00B |
|
0.00 |
| 2019-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.379B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
